UNSPSC 51313420: Carbinoxamine maleate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H19ClN2O.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 02O55696WH, chemically known as pyridine, 2-(p-chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)- but more generally known as carbinoxamine maleate, which bears US NIH Compound Identifier 2564. European Medicines Agency schedules Carbinoxamine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01044MIG.

Most nations, for tariff and trade purposes, schedule carbinoxamine maleate under HS 29333999. As of Q4 2014, CARBINOXAMINE MALEATE remains US FDA's Preferred Term for this commodity. Carbinoxamine maleate bears US NLM identifiers UMLS ID C0304300 and NCI Concept Code C47432. SMILES: CN(C)CCOC(C1CCC(CC1)CL)C2CCCCN2.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51313420 Carbinoxamine maleate is a Commodity code that captures individual pharmaceutical products procured by state and local health agencies, counties, and cooperative purchasing alliances. The code's nominal scope—a specific antihistamine—diverges from the recent solicitation activity actually tagged under it, which centers on broader pharmaceutical procurement including naloxone, generic multi-source drugs, and over-the-counter products through state and cooperative purchasing vehicles. State and local buyers under this code range from county health departments (Seminole County, Florida) to state health commissions (Texas Health and Human Services Commission) to multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, which serves participating jurisdictions across Minnesota and Oregon). The work involves securing reliable supply chains for essential pharmaceutical inventories through competitive bidding and proposal-based procurement, with vendors typically required to demonstrate FDA compliance, cGMP certification, Drug Supply Chain Security Act compliance, supply-chain relationships with authorized wholesalers, and appropriate insurance coverage.

Recent activity shows three representative opportunities spanning 2026: Seminole County's IFB60459723LAS, an Invitation for Bid posted June 30, 2026 (due July 26, 2023, per the source record) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida; Texas HHS's RFI HHS0017013, posted April 3, 2026, gathering vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program; and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products across Minnesota and Oregon, posted January 20, 2026 with proposals due March 26, 2026, requiring vendor submissions through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and weighted 75 percent on price competitiveness. The code shows moderate activity across the South and Upper Midwest, though the tagging mismatch between the code's nominal scope and the actual procurements—which rarely specify carbinoxamine maleate itself—suggests either broad aggregation of pharmaceutical codes in state sourcing systems or inconsistent taxonomy application.